CLOs on the Move

Relmada

www.relmada.com

 
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.relmada.com
  • 880 Third Avenue 12th Floor
    New York, PA USA 10022
  • Phone: 646.876.3459

Executives

Name Title Contact Details
Brian Walter
 Vice President of Regulatory Affairs Profile

Similar Companies

MedFlight of Ohio

MedFlight of Ohio is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

City of Winston-Salem, NC

City of Winston-Salem, North Carolina, U.S.A. Local government. Contact City Link call 311; citylink@cityofws.org

KaloBios

KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.

PCE Health and Fitness (PCE)

PCE Health and Fitness (PCE) is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AO North America

AO North America is a Paoli, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.